Protagonist Therapeutics

Discovering and developing novel therapies through our proprietary peptide technology platform. #biotech #lifesciences #innovation

[Protagonist Therapeutics @ProtagonistTx]

Protagonist is pleased to return to the Jefferies Global Healthcare Conference. Today, CEO Dinesh V. Patel participated in a fireside chat — register to catch the replay here:
https://t.co/BblfAPpCAW

[Protagonist Therapeutics @ProtagonistTx]

News: Four abstracts highlighting rusfertide in polycythemia vera (PV) will be presented at the 2026 European Hematology Association Congress (EHA2026 Congress), taking place June 11-14, 2026, in Stockholm, Sweden.

The presentations include analyses from the randomized, controlled Phase 3 VERIFY study, as well as long-term results from the Phase 2 REVIVE and THRIVE open-label extension studies.

Read more in our press release: https://t.co/ANnLzTV8tz

[Protagonist Therapeutics @ProtagonistTx]

Led by our Chief Medical Officer and Stanford alum, Arturo Molina, Protagonist Therapeutics had the opportunity to host @StanfordMed PhD and post-doctoral students at our office to learn about careers in biotech and pharma.

Our team had a wonderful time connecting with the next generation of scientists who aspire to be at the forefront of innovative medicine. Thank you to all who attended and made this event a success!

[Protagonist Therapeutics @ProtagonistTx]

Thank you to all who joined us at #TIDESUSA 2026 in Boston!

It was an honor to have our Executive Vice President and Chief Discovery Officer Ashok Bhandari, PhD, give a keynote presentation on Protagonist's story of revolutionizing peptide drug discovery through our unique multi-component technology platform. He also presented on what's next for our company as we advance a next-generation oral IL-17 antagonist peptide for inflammatory diseases.

Discover more about how we're addressing unmet needs with peptide technology: https://t.co/4nXHeT8OY3

[Protagonist Therapeutics @ProtagonistTx]

In case you missed it, catch @ProtagonistCEO Dinesh V. Patel on CNBC's Fast Money for a great discussion about our platform, partnerships, products, and pipeline.

Follow us for more updates. https://t.co/u4UFc02X7Q

[Protagonist Therapeutics @ProtagonistTx]

Today, we reported financial results for the first quarter 2026 and provided a corporate update.

See the full press release here: https://t.co/DWjZslQ7VO

[CNBC's Fast Money @CNBCFastMoney]

High-flying $PTGX is capitalizing on peptide production and licensing deals to help fuel its growing drug pipeline. @ProtagonistTx CEO Dinesh Patel breaks down the company's ongoing clinical trials and what could come next https://t.co/PyR4y8xY86

[Protagonist Therapeutics @ProtagonistTx]

Catch Protagonist CEO Dinesh Patel on CNBC’s Fast Money today between 5–6 PM ET. https://t.co/ITuX74cd7X

[Protagonist Therapeutics @ProtagonistTx]

Protagonist has exercised its right to opt out of the 50:50 U.S. profit and loss sharing arrangement under our worldwide license and collaboration agreement with Takeda for rusfertide, an investigational first-in-class hepcidin mimetic peptide. Rusfertide is now under U.S. Food and Drug Administration (FDA) Priority Review for the treatment of adults with polycythemia vera (PV).

Read more: https://t.co/mAWPAFZlw4

[Protagonist Therapeutics @ProtagonistTx]

"The first approval is just the beginning." - President and @ProtagonistCEO Dinesh V. Patel in an interview with @BiotechTV this past February.

From Protagonist's pioneering work in peptide therapeutics over 13 years ago to our expanding development programs in obesity and I&I today, our team is driven to tackling unmet medical needs with the power of peptide drug discovery and development.

Watch the full interview to learn more about our peptide technology platform and what's on the horizon for our company: https://t.co/HDAhs6oMGm

[Protagonist Therapeutics @ProtagonistTx]

For patients living with polycythemia vera, fatigue is much more than just feeling tired.

In an interview with @cure_today, one patient describes how PV-related fatigue combined with fatigue from phlebotomies used to manage her disease takes a toll on her quality of life. https://t.co/j2sGzxIZ1T

[Protagonist Therapeutics @ProtagonistTx]

Today we are pleased to announce presentation of one-year Phase 3 Data for ICOTYDE™ (icotrokinra) in moderate-to-severe plaque psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting.

The data demonstrate lasting skin clearance and a favorable safety profile in a once-daily pill for moderate-to-severe plaque psoriasis, with results further supporting the differentiated profile of ICOTYDE, licensed to Janssen Biotech, Inc., a Johnson & Johnson company.

https://t.co/b42xlSZyIX

[Protagonist Therapeutics @ProtagonistTx]

What a week for all of us at Protagonist! After celebrating the FDA Approval of ICOTYDE, we are thrilled to be recognized on the Nasdaq Tower in Times Square as a Fast 500 company. Ranking among the fastest-growing innovative companies in North America is a powerful validation of our innovation platform. To our customers, partners, and every member of the Protagonist family: This moment belongs to you. We’re just getting started. Looking forward to what's yet to come.

#PTGX #NASDAQ #BayAreaFast500 #Biotech #Innovation

[Protagonist Therapeutics @ProtagonistTx]

Today the FDA approved ICOTYDE™ (icotrokinra), the first targeted oral peptide option for first-line systemic treatment of plaque psoriasis.

This milestone reflects the power of our science and platform. Thank you to the PTGX team, Johnson & Johnson, investigators and patients who made it possible.

Read more: https://t.co/0TNwYudXbD

[Protagonist Therapeutics @ProtagonistTx]

Happy International Women's Day! This year's theme, #GiveToGain, encourages a mindset of generosity and collaboration in support of women's advancement to create a better future for all.

We are proud of our Protagonist team for exemplifying this sentiment and celebrate their successes and contributions as we pursue our mission to improve patient lives. #IWD2026

[Protagonist Therapeutics @ProtagonistTx]

Today, Protagonist and Takeda announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for rusfertide, an investigational, first-in-class hepcidin mimetic peptide therapeutic for the treatment of adults with polycythemia vera (PV).

Read more details in our latest press release: https://t.co/NTylXEIowQ

[Protagonist Therapeutics @ProtagonistTx]

Today is #RareDiseaseDay! 300 million people worldwide live with a rare disease and each one of their journeys is unique, as represented by our employees' zebra cookie creations.

From diagnostic odysseys to lack of approved treatments, those affected by rare diseases face numerous challenges that must be addressed with scientific innovation, ongoing advocacy, and increased awareness.

At Protagonist Therapeutics, patient stories and hope inspire what we do every day as we work towards bringing groundbreaking solutions and a brighter future for those living with polycythemia vera (PV).

[Protagonist Therapeutics @ProtagonistTx]

As communities gather worldwide to recognize #RareDiseaseDay on February 28th, we asked our Vice President of Clinical Ops, Antonieta Sosa, what moments in her work reinforce the importance of what we do for patients living with a rare disease like polycythemia vera (PV).

[Protagonist Therapeutics @ProtagonistTx]

Today, we reported financial results for the fourth quarter and full year 2025 and provided a corporate update.

See the full press release here: https://t.co/EZgaafnvQf